2025 年全球 CD39 标靶治疗临床试验、治疗方法与市场机会

Global CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025

出版日期: 2025年01月01日 | 出版商:

KuicK Research | 英文 100 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

CD39 标靶治疗已成为调节多种疾病免疫反应的一种有前途的策略。CD39 作为影响嘌呤讯号通路的关键外核甘酸酶，从而调节免疫活化和抑制之间的平衡。CD39 透过将 ATP 转化为 AMP，然后透过 CD73 进一步转化为腺甘，从而帮助建立免疫抑制微环境。这种环境对肿瘤特别有利，但在慢性感染和自体免疫疾病中也发挥作用。阻断 CD39 活性可能会恢復免疫功能并改善这些情况下患者的预后。

在肿瘤学中，CD39 对肿瘤微环境 (TME) 中的免疫抑制的贡献已得到充分证实。肿瘤常利用 CD39-CD73-腺甘轴来逃避免疫监视，导致免疫细胞耗竭和抗肿瘤反应受损。调节性 T 细胞 (Treg) 和 CD8+ T 细胞上 CD39 水平升高与多种恶性肿瘤预后不良有关。使用针对 CD39 的单株抗体（例如 IPH5201），可以重新激发免疫系统，更有效地对抗肿瘤细胞。IPH5201 由 Innate Pharma 和阿斯特捷利康共同开发，目前正在研究与免疫检查点抑制剂 (ICI) 联合使用以增强实体瘤患者的免疫反应。

除了癌症之外，CD39 标靶疗法也可能用于其他疾病，特别是慢性病毒感染、自体免疫疾病和败血症。在爱滋病毒、结核病和恰加斯病等慢性传染病中，CD39 参与免疫衰竭和抑制，阻止有效的免疫反应。阻断CD39可能逆转免疫功能障碍并提高人体消除病原体的能力。在免疫系统过度活跃的自体免疫疾病中，针对 CD39 可能有助于重新平衡调节性 T 细胞的抑制功能，这对于防止组织损伤至关重要。

由于单核细胞和巨噬细胞上的 CD39 表现对于控制发炎非常重要，因此针对 CD39 的治疗潜力也延伸至败血症。在败血症中，实现平衡的免疫反应对于有效控制感染同时减少组织损伤至关重要。透过抑制 CD39 活性，治疗干预可以抑制过度发炎并恢復免疫稳态，代表了对抗这种严重病理的新策略。

CD39 标靶治疗的临床进展仍处于早期阶段，其中有几种候选药物正在进行临床试验，特别是第 2 期试验。其中，IPH5201脱颖而出，成为领先的候选药物，在临床前和早期临床试验中均显示出良好的结果。这些抗体不仅在肿瘤学领域进行评估，而且在 CD39 在免疫调节中发挥重要作用的各种慢性疾病中进行评估。透过聚焦 CD39，这些疗法旨在增强免疫抑製或功能障碍情况下的免疫反应。

未来，针对CD39的治疗的潜在应用前景十分深远。将抗 CD39 抗体与其他疗法（例如免疫检查点抑制剂或抗病毒药物）结合，可以产生协同效应并提供增强免疫反应的机会。然而，课题依然存在，特别是关于 CD39 在不同疾病和患者群体中的环境相关功能。实现免疫活化和抑制之间的精确平衡对于安全有效地实施这些疗法至关重要。随着临床试验的进展和更多数据的收集，CD39 标靶疗法可能成为个人化医疗的基本组成部分，从而实现精确和可控的免疫反应，有效治疗各种疾病。

本报告研究了全球 CD39 标靶治疗市场，并概述了市场以及药物趋势、临床试验趋势、区域趋势以及参与市场的公司的竞争格局。

First CD39 Targeted Therapy Approval Expected By 2029
CD39 Targeted Therapies In Clinical Trials: > 15 Therapies
CD39 Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase
CD39 Targeted Therapy Research and Development Trends By Indication
CD39 Targeted Therapies Proprietary Technologies Platforms By Company

CD39 targeting therapies are emerging as a promising strategy for modulating immune responses in a range of diseases. CD39 serves as a vital ectonucleotidase that influences the purinergic signaling pathway, thereby regulating the equilibrium between immune activation and suppression. By converting ATP into AMP, which is further transformed into adenosine by CD73, CD39 is instrumental in establishing an immunosuppressive microenvironment. This environment is particularly advantageous for tumors but also plays a role in chronic infections and autoimmune diseases. Inhibiting CD39 activity may restore immune functionality and enhance patient outcomes in these contexts.

In the realm of oncology, the contribution of CD39 to immune suppression within the tumor microenvironment (TME) is well-established. Tumors frequently utilize the CD39-CD73-adenosine axis to evade immune surveillance, resulting in immune cell exhaustion and diminished anti-tumor responses. Elevated levels of CD39 on regulatory T cells (Tregs) and CD8+ T cells have been associated with unfavorable prognoses in various malignancies. By employing monoclonal antibodies that target CD39, such as IPH5201, it is possible to reactivate the immune system to more effectively combat tumor cells. IPH5201, which is being developed by Innate Pharma and AstraZeneca, is currently under investigation in conjunction with immune checkpoint inhibitors (ICIs) to enhance the immune response in patients with solid tumors.

In addition to cancer, CD39-targeting therapies show considerable potential for addressing other diseases, particularly chronic viral infections, autoimmune disorders, and sepsis. In the context of chronic infections like HIV, tuberculosis, and Chagas disease, CD39 is implicated in immune exhaustion and suppression, which obstructs effective immune responses. By inhibiting CD39, there is a possibility of reversing immune dysfunction and improving the body's capacity to eliminate pathogens. In autoimmune disorders, where there is an overactivation of the immune system, the targeting of CD39 may aid in reestablishing equilibrium by enhancing the inhibitory function of regulatory T cells, which are vital for averting tissue damage.

The therapeutic promise of targeting CD39 also encompasses sepsis, as CD39 expression on monocytes and macrophages is instrumental in regulating inflammation. In the context of sepsis, achieving a balanced immune response is crucial to mitigate tissue injury while effectively managing infection. By inhibiting the activity of CD39, therapeutic interventions could diminish excessive inflammation and restore immune homeostasis, presenting a novel strategy for addressing this critical condition.

The clinical advancement of therapies aimed at CD39 is still in its nascent phase, with several candidates progressing through clinical trials, particularly in Phase 2. Among these, IPH5201 stands out as a leading candidate, demonstrating encouraging outcomes in both preclinical and early-phase clinical investigations. These antibodies are being assessed not only in oncology but also across a range of chronic conditions where CD39 plays a significant role in immune regulation. By focusing on CD39, these therapies seek to bolster immune responses in scenarios characterized by immune suppression or dysfunction.

Looking forward, the potential uses of CD39-targeting therapies are extensive. The integration of anti-CD39 antibodies with other treatment modalities, such as immune checkpoint inhibitors or antiviral therapies, presents the opportunity for synergistic effects, thereby enhancing the immune response. Nonetheless, challenges persist, particularly concerning the context-dependent function of CD39 across various diseases and patient demographics. Achieving a precise balance between immune activation and suppression will be essential for the safe and effective implementation of these therapies. As clinical trials advance and additional data is collected, therapies targeting CD39 may emerge as a fundamental component of personalized medicine, effectively addressing various diseases through the precise and controlled modulation of immune responses.

1. Introduction To CD39 Targeting Therapies

1.1 Overview
1.2 Role of CD39 & Emergence As Therapeutic Target
1.3 Discovery of CD39 & Development Of Targeting Therapies

2. CD39 Targeting Therapies Mechanism Of Action

2.1 CD39 Inhibition
2.2 CD39 Agonism

3. Current CD39 Targeting Therapy Approaches

3.1 Antibodies
3.2 Nucleic Acid Therapeutics
3.3 Small Molecule Inhibitors

4. Global CD39 Targeted Therapies Clinical Trials Overview

4.1 By Company
4.2 By Indication
4.3 By Country
4.4 By Phase

5. CD39 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase II

6. Global CD39 Targeting Therapy Market Trends & Developments

6.1 Current Market Outline
6.2 Future Market Opportunities

7. Role Of CD39 Targeting Therapies By Indication: Clinical Development & Collaborations

7.1 Cancer
7.2 Autoimmune & Inflammatory Diseases
7.3 Cardiovascular Diseases
7.4 Infections

8. CD39 Targeted Therapies Technology Platforms

8.1 OligoCreator & LNAplus Platforms - Secarna Pharmaceuticals
8.2 Unnamed Platforms - Biotheus
8.3 Unnamed Platform - Adimab
8.4 OriAb Antibody Discovery Platform - Oricell Therapeutics
8.5 TMAb Platform - Sensei Biotherapeutics

9. Global CD39 Targeted Therapies Market Dynamics

9.1 Market Drivers & Opportunities
9.2 Market Challenges & Restraints

10. Competitive Landscape

10.1 Adimab
10.2 Arcus Biosciences
10.3 Biotheus
10.4 BrightPath Biotherapeutics
10.5 Elpiscience Biopharmaceuticals
10.6 Innate Pharma
10.7 Orega Biotech
10.8 OriCell Therapeutics
10.9 Secarna Pharmaceuticals
10.10 Trishula Therapeutics

简介目录图表

List of Figures

Figure 1-1: CD39/CD73/A2AR Pathway
Figure 1-2: Role Of Adenosine In Immune Regulation
Figure 1-3: Effects Of CD39 & Adenosine On Immune Cells
Figure 1-4: Discovery Of CD39 & Developmental Milestones

Figure 2 -1: CD39 Inhibition - Mechanism

Figure 2-2: CD39 Agonism - Mechanism
Figure 3-1: TTX-030: Mechanism of Action
Figure 3-2: Oligonucleotides - Benefits
Figure 4-1: Global - CD39 Targeted Therapies In Clinical Trials By Company (Number), 2025
Figure 4-2: Global - CD39 Targeted Therapies In Clinical Trials By Indication (Number), 2025
Figure 4-3: Global - CD39 Targeted Therapies In Clinical Trials By Country (Number), 2025
Figure 4-4: Global - CD39 Targeted Therapies In Clinical Trials By Phase (Number), 2025
Figure 7-1: Role Of CD39 In Cancer
Figure 7-2: ARC-25 Phase I/Ib (NCT05891171) Study - Initiation & Completion Year
Figure 7-3: MATISSE Phase II (NCT05742607) Study - Initiation & Completion Year
Figure 7-4: ELTIVATE/TTX-030-003 Phase II (NCT06119217) Study - Initiation & Completion Year
Figure 7-5: ES014-IIT-01 Phase II (NCT06543056) Study - Initiation & Completion Year
Figure 7-6: Role Of CD39 In Modulating Inflammatory Responses
Figure 7-7: Role Of CD39 In Cardiovascular Diseases
Figure 7-8: Role Of CD39 In Infections
Figure 8-1: Secarna Pharmaceuticals - OligoCreator Platform
Figure 8-2: Adimab - Proprietary Platform
Figure 8-3: Sensei Biotherapeutics - TMAb Platform
Figure 9-1: Global CD39 Targeted Therapies Market - Market Drivers & Opportunities
Figure 9-2: Global CD39 Targeted Therapies Market - Market Challenges & Restraints